JAK inhibitors may fall to 2nd-line due to safety concerns

By Nho, Byung Chul | translator Alice Kang

21.09.16 06:30:00

가나다라 0

Health authorities are collecting opinion on clinical efficacy from academic societies, etc.

Prioritized safety in patient drug intake… is actively considering advancing regulatory science for public health

FDA restricts Xeljanz from first-line to second-line treatment in response to its safety issue

With the health authorities seriously considering changing the reimbursement standards for Janus kinases (JAK) inhibitors which have recently been caught up in controversy over its safety issues, what the results will be is gaining industry-wide attention.

According to industry sources, the Ministry of Health and Welfare (MOHW) and the Health Insurance Review and Assessment Service (HIRA) have been collecting opinions from relevant academic societies on the clinical efficacy and sequential therapy (first-line·second-line treatment) of JAK inhibitors for consideration.

Although there had been cases where the authorities had removed drugs from the insurance benefit list according to the r

Nho, Byung Chul(sasiman@dailypharm.com)

If you want to see the full article, please JOIN US (click)